Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome

Hyperinflammatory syndromes comprise a heterogeneous group of disorders characterized by severe inflammation, multiple organ dysfunction, and potentially death. In response to antigenic stimulus (e.g., SARS-CoV-2 infection), overactivated CD8+ T-cells and macrophages produce high levels of proinflam...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Pharmacol
Egile Nagusiak: Huarte, Eduardo, Peel, Michael T., Verbist, Katherine, Fay, Brittany L., Bassett, Rachel, Albeituni, Sabrin, Nichols, Kim E., Smith, Paul A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2021
Gaiak:
Pharmacology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107823/
https://ncbi.nlm.nih.gov/pubmed/33981229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.650295
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak